(Q36945023)

17 August 2017

1 reference

title

The safety of rosuvastatin: effects on renal and hepatic function (English)

1 reference

17 August 2017

Robert M Guthrie

1

1 reference

17 August 2017

Daniel R Martin

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Drug Safety

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

573-581

1 reference

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

The IDEAL cholesterol: lower is better

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

How safe is aggressive statin therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Statin safety: lessons from new drug applications for marketed statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Statins and liver toxicity: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Autoimmune hepatitis revealed by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Defining patient risks from expanded preventive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Statins and hepatotoxicity: focus on patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Liver transplantation for acute liver failure from drug induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Getting more people on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Effect of pravastatin on proteinuria in patients with well-controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Progression of chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

An assessment of statin safety by nephrologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Benefit versus risk in statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

Statin safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.573

21 January 2018

Identifiers

DOI

10.1517/14740338.6.5.573

1 reference

17 August 2017

1 reference